BLTE · Belite Bio, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| EPS - Basic | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $352.93M | $31.68M | $88.16M | $42.09M | $17.34M | $25.62M | $2.02M |
| Accounts Receivable | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - |
| Current Assets | $494.27M | $147.07M | $89.94M | $42.81M | $17.43M | - | - |
| Total Assets | $780.56M | $152.13M | $94.64M | $44.27M | $18.35M | - | - |
| Current Liabilities | $9.88M | $6.05M | $3.63M | $2.10M | $1.64M | - | - |
| Long-term Debt | - | - | - | - | - | - | - |
| Total Liabilities | $10.07M | $6.31M | $4.21M | $2.77M | $1.64M | - | - |
| Stockholders' Equity | $770.49M | $145.82M | $90.43M | $41.50M | ($15.09M) | ($7.04M) | ($3.74M) |
| Retained Earnings | ($185.26M) | ($107.65M) | ($71.50M) | ($39.87M) | ($27.22M) | ($17.60M) | - |
Cash Flow
| Line item | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - |
| Return on assets | - | - | - | - | - | - | - |
| Return on equity | - | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 50.02 | 24.31 | 24.76 | 20.35 | 10.66 | - | - |
| Quick ratio | 50.02 | 24.31 | 24.76 | 20.35 | 10.66 | - | - |
| Cash ratio | 35.71 | 5.24 | 24.27 | 20.00 | 10.61 | - | - |
| Leverage | |||||||
| Debt / Equity | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - |
| Equity multiplier | 1.01 | 1.04 | 1.05 | 1.07 | -1.22 | - | - |
| Liabilities / Assets | 0.01 | 0.04 | 0.04 | 0.06 | 0.09 | - | - |
| Efficiency | |||||||
| Asset turnover | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | 428.4% | 61.3% | 117.9% | - | -114.5% | -88.2% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BELITE BIO against the 5 most active filers in the same SIC group.